Andere Sprachen Akeso, Inc.

Aktien

A2P200

KYG0146B1032

9926

Markt geschlossen - Hong Kong S.E. Andere Börsenplätze 10:08:16 02.05.2024			% 5 Tage	% 1. Jan.
48,8 ^HKD	+1,35 %		+3,94 %	+5,17 %

24.04.	Ergänzungsantrag von Akeso für Gebärmutterhalskrebsmedikament von chinesischer Aufsichtsbehörde akzeptiert	MT
24.04.	National Medical Products Administration akzeptiert den ergänzenden Zulassungsantrag von Akeso, Inc. für (Cadonilimab, Pd-1/Ctla-4) als Erstlinienbehandlung von Gebärmutterhalskrebs	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Akeso’s Supplemental New Drug Application for Cervical Cancer Drug Accepted by Chinese Regulator	24.04.
National Medical Products Administration Accepted the Supplemental New Drug Application by Akeso, Inc. for (Cadonilimab, Pd-1/Ctla-4) as First-Line Treatment for Cervical Cancer	24.04.
Summit Therapeutics Inc. - Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024	25.03.
Akeso to Raise Over HK$1 Billion Via Share Sale	22.03.
Akeso Logs First-Ever Profit in 2023; Beats EPS Forecast	19.03.
Akeso, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	18.03.
Akeso Announces the First Patient Dosed in Phase III Trial of Cadonilimab(PD-1/CTLA-4) Combined with Chemotherapy versus Tislelizumab Combined with Chemotherapy in First-Line Treatment of PD-L1 negative NSCLC	06.03.
Akeso Books First-Ever Profit in 2023; Shares Fall 5%	05.03.
Akeso, Inc. Provides Consolidated Earnings Guidance for the Year Ended December 31, 2023	05.03.
Gilead Sciences pauses enrollment for cancer treatment in solid tumor trials	16.02.
Summit Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results and Operational Progress Call on February 20, 2024	15.02.
Akeso Unit Buys 35% Stake in Biopharmaceutical Firm from Dawnrays; Akeso Shares Slide 3%	09.02.
Summit Therapeutics to Present at Oppenheimer's 34th Annual Healthcare Life Sciences Conference	08.02.
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023	08.02.
Akeso Presents Promising Results of Cadonilimab and Lenvatinib in Combination with TACE in uHCC at 2024 ASCO GI	23.01.
Akeso to Present at the 42nd Annual J.P. Morgan Healthcare Conference and Share Its Corporate & Innovative Clinical Development Roadmap	08.01.
Akeso, Inc. Announces Innovative Clinical Development Roadmap	08.01.
Chinese Medical Regulator Accepts Akeso’s Supplemental New Drug Application for Gastric Cancer Therapy	05.01.
Akeso, Inc. Announces National Medical Products Administration Accepts the Supplemental New Drug Application for Kai Tan Ni (Cadonilimab, PD-1/CTLA-4) in Combination with Chemotherapy as First-Line Treatment for Gastric Cancer	05.01.
Akeso Published Results from CD47 Antibody Ligufalimab in Combination with Azacitidine for Newly Diagnosed Higher-Risk Myelodysplastic Syndrome and Treatment-naive Acute Myeloid Leukemia at ASH 2023	18.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Akeso, Inc.

Aktien

A2P200

KYG0146B1032

9926

Andere Sprachen

Filter